Bristol-Myers' gets early approval of combo cancer treatment

The first combination of breakthrough drugs that boost the immune system to fight cancer has been approved, giving maker Bristol-Myers Squibb an early lead over competitors testing their own combos in a pharmaceutical gold rush of sorts.

The Food and Drug Administration has given accelerated approval to a regimen combining the New York-based drugmaker's two immuno-oncology drugs, Opdivo and Yervoy, to treat patients with advanced melanoma who have a particular genetic variation.

Together, the drugs slowed or temporarily stopped in 60 percent of patients, versus 11 percent who only received Yervoy, in a study.

But with a list price of up to a quarter-million dollars for the combo treatment, unless insurance plans negotiate huge discounts, many likely won't be able to afford their portion of the cost.


Explore further

FDA approves new melanoma drug from Bristol-Myers

© 2015 The Associated Press. All rights reserved.

Citation: Bristol-Myers' gets early approval of combo cancer treatment (2015, October 1) retrieved 17 September 2019 from https://medicalxpress.com/news/2015-10-bristol-myers-early-combo-cancer-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
22 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more